Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Day One Biopharmaceuticals (DAWN) Interest & Investment Income (2022 - 2025)

Day One Biopharmaceuticals (DAWN) has disclosed Interest & Investment Income for 4 consecutive years, with $4.1 million as the latest value for Q4 2025.

  • For Q4 2025, Interest & Investment Income fell 31.48% year-over-year to $4.1 million; the TTM value through Dec 2025 reached $18.5 million, down 6.24%, while the annual FY2025 figure was $18.5 million, 6.24% down from the prior year.
  • Interest & Investment Income was $4.1 million for Q4 2025 at Day One Biopharmaceuticals, down from $4.6 million in the prior quarter.
  • The five-year high for Interest & Investment Income was $6.1 million in Q4 2024, with the low at $2000.0 in Q1 2022.
  • Historically, Interest & Investment Income has averaged $3.8 million across 4 years, with a median of $4.3 million in 2024.
  • The largest annual shift saw Interest & Investment Income soared 173200.0% in 2023 before it crashed 31.48% in 2025.
  • Over 4 years, Interest & Investment Income stood at $2.7 million in 2022, then skyrocketed by 88.87% to $5.0 million in 2023, then increased by 20.46% to $6.1 million in 2024, then crashed by 31.48% to $4.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Interest & Investment Income were $4.1 million in Q4 2025, $4.6 million in Q3 2025, and $4.7 million in Q2 2025.